Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Two-Year US Pharmacovigilance Report on Brodalumab

Open access

Abstract

INTRODUCTION: Brodalumab is a human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. In the United States, brodalumab carries a boxed warning about suicidal ideation and behavior; however, no causal association was established between brodalumab and suicides reported during pivotal trials. We have previously reported results from an analysis of 1-year pharmacovigilance data in patients in the United States who took brodalumab, in which the most commonly reported adverse event was psoriasis flare. There were no completed suicides, suicide attempts, or serious fungal infections. Here, we provide a 2-year US pharmacovigilance report. METHODS: This analysis summarizes pharmacovigilance data reported to Ortho Dermatologics by US patients and healthcare providers from August 15, 2017, through August 14, 2019. The most common adverse events listed in the brodalumab package insert (incidence ≥ 1%; arthralgia, headache, fatigue, diarrhea, oropharyngeal pain, nausea, myalgia, injection-site reactions, influenza, neutropenia, and tinea infections) and adverse events of special interest are reported. RESULTS: Data were collected from 2677 patients in the United States who took brodalumab, with an estimated exposure of 1656 patient-years. Arthralgia was the most commonly reported adverse event (73 events; 0.04 events per patient-year). No suicide attempts or completed suicides were reported; there were 25 reports of depression. There were 46 serious infections and no serious fungal infections. One event of Crohn's disease was reported, which led to discontinuation. There were 13 malignancies, with none deemed related to brodalumab. CONCLUSIONS: This pharmacovigilance report supports the safety profile of brodalumab previously reported from long-term analyses of clinical trials and 1-year pharmacovigilance data.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13555-020-00472-x

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Exposure-adjusted AEs of special interest per PY. The exposure-adjusted event rate per PY is the number of events per 1656 PY of exposure. AE adverse event; PY patient-year
Fig. 1 Exposure-adjusted AEs of special interest per PY. The exposure-adjusted event rate per PY is the number of events per 1656 PY of exposure. AE adverse event; PY patient-yearCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 24

Metadata

Authors
Lebwohl, M., Leonardi, C., Wu, J. J., Armstrong, A., Rawnsley, N., Merchant, M., Alexander, B., & Jacobson, A.
Affiliations
  • Icahn School of Medicine at Mount Sinai (US)
  • Saint Louis University (US)
  • Dermatology Research and Education Foundation (US)
  • University of Southern California (US)
  • Bausch Health (United States) (US)
Corresponding author
Lebwohl, Mark
Venue
Dermatology and Therapy
Published
2020-12-18
Volume
11
Issue
1
Pages
173-180
ISSN
  • 2190-9172 (ISSN-L)
  • 2193-8210
OpenAlex
W3113634853
Cited by
24
References
16
Citations by year
2026: 1 · 2025: 3 · 2024: 4 · 2023: 5 · 2022: 8 · 2021: 3
FWCI
1.40
Type
journal article
Language
en
Open access
Licence
Locations
  • Dermatology and Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Ortho Dermatologics
  • Bausch Health
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
Keywords
brodalumab, pharmacovigilance, adverse drug reactions, plaque psoriasis, suicide risk, psoriasis flare, joint pain, serious infections, Crohn's disease, cancer, drug safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Two-Year US Pharmacovigilance Report on Brodalumab. https://app.cochat.ai/papers/10.1007/s13555-020-00472-x
The paper
Lebwohl, M., Leonardi, C., Wu, J. J., Armstrong, A., Rawnsley, N., Merchant, M., Alexander, B., & Jacobson, A. (2021). Two-Year US Pharmacovigilance Report on Brodalumab. Dermatology and Therapy. https://doi.org/10.1007/s13555-020-00472-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.